Risk factors
Protara Therapeutics (TARA) risk factors
Item 1A of every Protara Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
54 risks, 2 dropped, 12 reworded since the prior year. Updates expand references to Fast Track Designation for TARA-002 in pediatric lymphatic malformations and adjust warrant details.
Filed Mar 10, 2026 - FY2024 10-K risk factors
56 risks. Clinical stage biopharmaceutical company with no revenue, developing TARA-002 and IV Choline Chloride. Heavily dependent on third-party manufacturers, Chugai agreements, and external clinical trial enrollment. Subject to extensive regulatory requirements and ongoing financing needs.
Filed Mar 05, 2025